Scarica l'app Stockscreener
7.6247
1.45%
-0.1121
Dopo l'orario di chiusura:
7.50
-0.1247
-1.64%
Precedente Chiudi:
$7.7368
Aprire:
$7.39
Volume 24 ore:
1,608
Relative Volume:
0.25
Capitalizzazione di mercato:
$4.48M
Reddito:
-
Utile/perdita netta:
$-8.28M
Rapporto P/E:
-1.3713
EPS:
-5.56
Flusso di cassa netto:
$-7.99M
1 W Prestazione:
+1.66%
1M Prestazione:
+13.89%
6M Prestazione:
-26.15%
1 anno Prestazione:
-72.77%
Intervallo 1D:
$7.39
$7.6399
Intervallo di 1 settimana:
$7.3753
$7.7368
Portata 52W:
$5.01
$54.95
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Nome
Quoin Pharmaceuticals Ltd Adr
Settore
Industria
Telefono
97299741444
Indirizzo
23 HATA'AS STREET, KFAR SABA
Confronta QNRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
7.6247 | 4.47M | 0 | -8.28M | -7.99M | -5.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Quoin Pharmaceuticals Ltd Adr Borsa (QNRX) Ultime notizie
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 2.8% – Still a Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials By Investing.com - Investing.com Nigeria
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
MINISO Group Holding Limited Unsponsored ADR (NYSE:MNSO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.2% – Should You Sell? - Defense World
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
FDA grants rare pediatric disease designation for Netherton syndrome drug - Investing.com
Quoin announces FDA clearance to initiate second whole body QRX003 NS study - TipRanks
FDA clears Quoin’s new Netherton syndrome study By Investing.com - Investing.com South Africa
FDA clears Quoin’s new Netherton syndrome study - Investing.com
Quoin Pharmaceuticals announces EMA grants ODD for QRX003 - TipRanks
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data By Stocktwits - Investing.com India
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals announces initial positive clinical data for QRX003 - TipRanks
Quoin reports progress in pediatric skin disorder study By Investing.com - Investing.com India
Quoin Pharmaceuticals reports Q1 EPS ($6.50) vs ($38.73) last year - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains Nasdaq compliance - Investing.com
Quoin Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Quoin Pharmaceuticals releases second episode of ‘Living with Netherton’ series - TipRanks
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com India
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - The Globe and Mail
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com India
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment By Investing.com - Investing.com South Africa
What Is Going On With Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX)? - stocksregister.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles By Investing.com - Investing.com South Africa
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com India
Quoin seeks patent for skin disease treatment QRX003 By Investing.com - Investing.com South Africa
Quoin seeks patent for skin disease treatment QRX003 - Investing.com India
QNRX Stock Plummets to 52-Week Low at $0.28 Amid Market Struggles - Investing.com India
QNRX Stock Plummets to 52-Week Low at $0.28 Amid Market Struggles By Investing.com - Investing.com South Africa
NVIDIA Corp (NVDA) Shares Up Despite Recent Market Volatility - The News Heater
Quoin Pharmaceuticals reports promising Netherton Syndrome treatment - Investing.com
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com
Earnings call transcript: Quoin Pharmaceuticals Q4 2023 sees stock volatility - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
Zacks Small Cap Research Equity Research & Stock Reports - Research Tree
symbol__ Stock Quote Price and Forecast - CNN
Quoin Pharmaceuticals Ltd Adr Azioni (QNRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Quoin Pharmaceuticals Ltd Adr Azioni (QNRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Myers Michael | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.45 |
555,556 |
250,000 |
602,808 |
| Dunn Gordon | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.45 |
122,221 |
54,999 |
151,077 |
| Culverwell Anthony James | Director |
Dec 23 '24 |
Buy |
0.45 |
100,000 |
45,000 |
100,317 |
| Dunn Gordon | Chief Financial Officer |
Sep 10 '24 |
Buy |
0.81 |
20,000 |
16,200 |
28,856 |
| Dunn Gordon | Chief Financial Officer |
Sep 09 '24 |
Buy |
0.79 |
8,856 |
7,005 |
8,856 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):